Wiecek A, Chudek J, Nieszporek T, Kokot F
Katedry i Kliniki Nefrologii Sl. AM, Katowicach.
Pol Arch Med Wewn. 1992 Dec;88(6):451-7.
This paper summarizes results of rhuEPO--treatment obtained by different authors in 27 patients with a myelodysplastic syndrome (MDS). Only 1/3 of all patients with a MDS were responsive to rhuEPO treatment, while in 2/3 of these subjects no amelioration of anaemia was noticed, even after extremely high doses of this hormone. A detailed description of a patient with MDS, which was observed by the authors, is presented. In this patient the anaemia was refractive even after very high doses of rhuEPO administered for 10 weeks.
本文总结了不同作者对27例骨髓增生异常综合征（MDS）患者进行重组人促红细胞生成素（rhuEPO）治疗的结果。所有MDS患者中只有1/3对rhuEPO治疗有反应，而在这些患者中的2/3，即使使用极高剂量的这种激素，也未观察到贫血症状有所改善。本文还详细描述了作者观察到的1例MDS患者。该患者即使在给予极高剂量的rhuEPO并持续治疗10周后，贫血仍难以纠正。
